Experimental Study of Anti-Interventional Endothelial Progenitor Cells Combined with Mesenchymal Stem Cells in Large Femoral Defects

Abstract

Mesenchymal stem cells (MSCs) and vascular endothelial progenitor cells (EPCs) have the potential for self-renewal and multi-directional differentiation. Their combination therapy is beneficial for treating orthopedic diseases. However, the role of antibiotic-interventional EPCs combined with MSCs in large femoral defects remains unclear. Rabbit MSCs and EPCs were isolated and EPCs were cultured in the presence of 1% green chain double antibody. The femoral segmental bone defect model was prepared and randomly divided into control group, MSCs group, EPCs group, EPCs + MSCs group, and autologous oxygen release nano-bionic scaffolds were combined with MSCs, EPCs, EPCs + MSCs followed by analysis of osteophytes by HE staining, bone density, ALP activity, TGF-β1 secretion by ELISA, and level of VEGF, Runx2 and OC by Real time PCR. MSCs, EPCs and combined treatment for large femoral bone defects can significantly improve osteophyte growth, promote bone density, increase ALP activity and TGF-β1 secretion, as well as increase VEGF, Runx2 and OC expression. Compared with control group, there was a significant difference (P < 0.05) with combined treatment group having more significant effect on bone repair. Antibioticintervention of EPCs combined with MSCs promotes osteogenic activity and bone repair ability in large femoral defects.